E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Japanese Encephalitis Hepatitis A |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To describe the safety of a single dose of JE CV in comparison with hepatitis A control vaccine in two age cohorts: children aged 2 to 5 years previously vaccinated with two doses of a mouse-brain-derived inactivated JE vaccine according to the national immunization schedule, and toddlers aged 12 to 24 months previously not vaccinated with any JE vaccine |
|
E.2.2 | Secondary objectives of the trial |
• To describe the immune response to JE before and after a single dose of JE CV in two age cohorts: children aged 2 to 5 years previously vaccinated with two doses of mouse-brain-derived inactivated JE vaccine according to the national immunization schedule, and toddlers aged 12 to 24 months previously not vaccinated with any JE vaccine • To describe the yearly persistence of immune response to JE after a single dose of JE CV in the study population |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provision of consent form signed by at least one parent or another legally acceptable representative, and by at least one independent witness. 2. Completion of vaccinations according to the national immunization schedule 3. Subject and parent/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures. 4. Previous receipt of two doses of a mouse-brain-derived JE vaccine at 12 to 15 months of age according to the national immunization schedule and aged 2 to 5 years on the day of inclusion. 5. Aged 12 to 24 months on the day of inclusion and have not received any JE vaccine. |
|
E.4 | Principal exclusion criteria |
1. Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination. 2. Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy. 3. Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances. 4. Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator. 5. Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of the immune response. 6. Receipt of hepatitis A vaccine. 7. History of flavivirus infection (confirmed either clinically, serologically or microbiologically). 8. Administration of any anti-viral within 2 months preceding the screening visit. 9. History of central nervous system disorder or disease. 10. Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia. 11. Planned participation in another clinical trial during the present trial period. 12. Receipt of any vaccine in the 4 weeks preceding the first trial vaccination. 13. Planned receipt of any vaccine in the 4 weeks following any trial vaccination. 14. Personal human immunodeficiency virus, hepatitis B or hepatitis C seropositivity in the blood sample taken at screening. 15. Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination. 16. Previous vaccination against flavivirus disease at any time before the trial other than a mouse-brain-derived JE vaccine given in a two-dose regimen at 12 to 15 months of age in accordance with the national immunization schedule. 17. Febrile illness or any acute illness/infection on the day of vaccination, according to investigator judgment History of seizures. 18. Previous vaccination against flavivirus disease. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection. 2. Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as Second Injection |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1 and 2. Day 0 up to Day 14 post-vaccination |
|
E.5.2 | Secondary end point(s) |
1. Percentage of Participants With Seroconversion to JE-CV Vaccine Antigens Following Administration of JE-CV Vaccination.
2. Summary of Geometric Mean Titers Against JE Antibodies Before and After JE-CV Vaccination |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1 and 2. Day 0 (pre-vaccination) and Day 28 after final vaccination |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last contact, Study includes a long term, 5 years follow-up post vaccination |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 5 |